TR200001981T2 - Farmasötik açıdan salınımı uzatılmış oral dozaj şekli - Google Patents

Farmasötik açıdan salınımı uzatılmış oral dozaj şekli

Info

Publication number
TR200001981T2
TR200001981T2 TR2000/01981T TR200001981T TR200001981T2 TR 200001981 T2 TR200001981 T2 TR 200001981T2 TR 2000/01981 T TR2000/01981 T TR 2000/01981T TR 200001981 T TR200001981 T TR 200001981T TR 200001981 T2 TR200001981 T2 TR 200001981T2
Authority
TR
Turkey
Prior art keywords
dosage form
extended
pharmaceutically
oral dosage
atpase inhibitor
Prior art date
Application number
TR2000/01981T
Other languages
English (en)
Turkish (tr)
Inventor
Karehill Per-Gunnar
Johan Lundberg Per
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200001981T2 publication Critical patent/TR200001981T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2000/01981T 1997-12-22 1998-12-17 Farmasötik açıdan salınımı uzatılmış oral dozaj şekli TR200001981T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II

Publications (1)

Publication Number Publication Date
TR200001981T2 true TR200001981T2 (tr) 2000-11-21

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01981T TR200001981T2 (tr) 1997-12-22 1998-12-17 Farmasötik açıdan salınımı uzatılmış oral dozaj şekli

Country Status (38)

Country Link
US (1) US6605303B1 (enExample)
EP (1) EP1043976B1 (enExample)
JP (1) JP4865945B2 (enExample)
KR (2) KR20060097069A (enExample)
CN (1) CN1171582C (enExample)
AR (1) AR017201A1 (enExample)
AT (1) ATE312602T1 (enExample)
AU (1) AU759634B2 (enExample)
BG (1) BG65028B1 (enExample)
BR (1) BR9814378A (enExample)
CA (1) CA2315261C (enExample)
CY (1) CY1106072T1 (enExample)
CZ (1) CZ299228B6 (enExample)
DE (1) DE69832816T2 (enExample)
DK (1) DK1043976T3 (enExample)
DZ (1) DZ2685A1 (enExample)
EE (1) EE04901B1 (enExample)
ES (1) ES2252875T3 (enExample)
HR (1) HRP20000380B1 (enExample)
HU (1) HUP0101437A3 (enExample)
IL (2) IL136827A0 (enExample)
IS (1) IS5524A (enExample)
MA (1) MA26576A1 (enExample)
MY (1) MY126555A (enExample)
NO (1) NO20003218L (enExample)
NZ (1) NZ505127A (enExample)
PL (1) PL193776B1 (enExample)
RU (1) RU2214232C2 (enExample)
SA (1) SA99191077B1 (enExample)
SE (1) SE9704869D0 (enExample)
SK (1) SK284988B6 (enExample)
TN (1) TNSN98229A1 (enExample)
TR (1) TR200001981T2 (enExample)
TW (1) TWI249410B (enExample)
UA (1) UA69397C2 (enExample)
WO (1) WO1999032091A1 (enExample)
YU (1) YU36700A (enExample)
ZA (1) ZA9811239B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE286394T1 (de) * 1995-09-21 2005-01-15 Pharma Pass Ii Llc Ein säurelabile omeprazol enthaltende arzneizusammensetzung und verfahren zu deren herstellung
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
ATE500815T1 (de) 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
WO2002045694A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
MXPA05003162A (es) 2002-09-26 2005-07-05 Yamanouchi Pharma Co Ltd Agentes mejoradores de absorbibilidad de droga.
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8679541B2 (en) * 2007-03-14 2014-03-25 Particle Dynamics International, Llc Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
RU2010119041A (ru) * 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
HRP20191559T1 (hr) 2013-02-13 2019-11-29 Redhill Biopharma Ltd Farmaceutski pripravci za liječenje infekcije bakterijom helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (enExample) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
KR100355130B1 (ko) * 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
DK1078628T3 (da) * 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
KR20010033428A (ko) 2001-04-25
CZ20002314A3 (cs) 2000-11-15
HK1034455A1 (en) 2001-10-26
ATE312602T1 (de) 2005-12-15
AU759634B2 (en) 2003-04-17
IL136827A (en) 2007-05-15
TWI249410B (en) 2006-02-21
SK284988B6 (sk) 2006-04-06
BR9814378A (pt) 2000-10-10
YU36700A (sh) 2003-01-31
US6605303B1 (en) 2003-08-12
EP1043976A1 (en) 2000-10-18
PL193776B1 (pl) 2007-03-30
IS5524A (is) 2000-06-08
CZ299228B6 (cs) 2008-05-21
BG104620A (en) 2001-04-30
CN1284866A (zh) 2001-02-21
AR017201A1 (es) 2001-08-22
AU1991299A (en) 1999-07-12
DZ2685A1 (fr) 2003-03-29
WO1999032091A1 (en) 1999-07-01
RU2214232C2 (ru) 2003-10-20
MY126555A (en) 2006-10-31
SE9704869D0 (sv) 1997-12-22
EE04901B1 (et) 2007-10-15
EE200000383A (et) 2001-12-17
NZ505127A (en) 2003-02-28
HRP20000380A2 (en) 2001-06-30
TNSN98229A1 (fr) 2005-03-15
SA99191077B1 (ar) 2006-07-11
DE69832816D1 (de) 2006-01-19
MA26576A1 (fr) 2004-12-20
DK1043976T3 (da) 2006-03-20
HRP20000380B1 (en) 2007-08-31
JP2001526211A (ja) 2001-12-18
ZA9811239B (en) 1999-06-22
NO20003218D0 (no) 2000-06-21
KR100755154B1 (ko) 2007-09-04
HUP0101437A2 (hu) 2001-10-28
EP1043976B1 (en) 2005-12-14
CN1171582C (zh) 2004-10-20
CA2315261A1 (en) 1999-07-01
PL341428A1 (en) 2001-04-09
SK8072000A3 (en) 2001-01-18
IL136827A0 (en) 2001-06-14
UA69397C2 (uk) 2004-09-15
ES2252875T3 (es) 2006-05-16
JP4865945B2 (ja) 2012-02-01
CA2315261C (en) 2008-02-12
BG65028B1 (bg) 2006-12-29
NO20003218L (no) 2000-08-22
CY1106072T1 (el) 2011-06-08
HUP0101437A3 (en) 2003-01-28
DE69832816T2 (de) 2006-08-31
KR20060097069A (ko) 2006-09-13

Similar Documents

Publication Publication Date Title
YU36700A (sh) Oralni farmaceutski oblik za doziranje sa produženim oslobađanjem
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
DE60132077D1 (de) Vitaminzusammenstellung mit verzögerter freigabe
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
PT1035834E (pt) Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
TR199800902T2 (xx) Ecza form�lasyonlar�.
DE69940674D1 (de) Orale verabreichung von adenosin analogen
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
NO20016346D0 (no) Ny formulering
TR199900413T2 (xx) �laca diren�li streptokoklar�n neden oldu�u pn�moni (pn�mokok) tedavisi i�in bir ila� yap�m�nda bir amoksisilin ve klavulanat kombinasyonunun kullan�m�.
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
AR014012A1 (es) Formula de liberacion prolongada
CO5031291A1 (es) Composicion farmaceutica
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
DE69927374D1 (de) Entzündungshemmende pharmazeutische formulierungen
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.